Content intended for healthcare professionals. By continuing, you confirm you are a HCP.
RSNA 2026 · Chicago
Meet Medimaps at RSNA
Medimaps builds imaging software that helps clinicians understand bone health, from the microarchitecture that determines whether bone will break to the fractures hiding in X-rays.
Nov 29 — Dec 3, 2026
See you at Booth #5728
South Hall Level 3 — AI Showcase
South Hall Level 3
Find Medimaps and Radiobotics at booth #5728
We're looking forward to meeting you in Chicago!
Who's attending
Meet the team
Book a meeting, grab a coffee, and learn about our bone health ecosystem.
Prof. Didier Hans, PhD, MBA
CEO, Co-Founder & Board Member
Ask me about the science and clinical evidence behind TBS®
Gino Fiore, MBA
Chief Commercial Officer
Ask me about global partnerships and modality integrations
Michael Lundemann, PhD
VP Global Customer Excellence
Ask me about support and customer experience after go-live
Book with Michael
Martin Bjerregaard Wied
Global Partnerships Manager
Ask me about reseller, distributor, and marketplace partnerships
Book with Martin
Ryan Hennen
US National Sales Director
Ask me about our bone health portfolio on DXA and X-ray
Book with Ryan
Tina Henkel
Account Executive, Midwest
Ask me about our bone health portfolio on DXA and X-ray
Book with Tina
Gina Jausoro
Account Executive, West
Ask me about our bone health portfolio on DXA and X-ray
Book with Gina
John Ault
Account Executive, Southeast
Ask me about our bone health portfolio on DXA and X-ray
Book with John
Serena Fisichella
Senior Clinical Support Specialist
Ask me about training your team on our bone health portfolio
Book with SerenaTBS Osteo™ · In the US and beyond
Get more from your DXA
While DXA measures BMD, an important indicator of fracture risk, it doesn’t capture the full picture.
Clinical confidence
Beyond bone density
TBS Osteo™ improves fracture-risk assessment beyond BMD to support more confident decisions, especially in normal or osteopenic BMD and secondary osteoporosis
Seamless integration
No new workflow
Fully integrated reporting across connected DXA systems — no added scan time or radiation — and results are sent to PACS as a DICOM structured report
Economic value
Reimbursed care
TBS Osteo™ supports institutional value through referrals and reimbursement alignment under four dedicated CPT® codes in the US, billable alongside DXA
Hardware partners
Runs on the DXA systems you already own
TBS Osteo™ integrates into leading DXA platforms, no new hardware required.
Not all hardware supports all versions of TBS Osteo™. Book a meeting with your Medimaps representative for more information.
Adding TBS® to DXA via TBS Osteo™ can help identify up to 30% of patients at risk of fracture who were classified as osteopenic by BMD alone.1
4.5M+
TBS® evaluations performed annually2
1,600+
peer-reviewed publications2
35+
clinical guidelines citing TBS®2
90+
countries with clinical deployments2
At the booth
Three good reasons to stop by booth #5728
- Walk through a live TBS Osteo™ report
- Check your DXA systems' compatability
- Talk through billing under the four dedicated CPT® codes
Rest of world
Visiting from outside the US?
RSNA brings the world together. Outside the US, our full portfolio is available.
AI fracture detection
RB Fracture™
One of Europe's most deployed AI fracture-detection tools. Decision support for paediatric and adult patients.
- CE-marked, Class IIa
- Available in 44+ countries
- NICE-approved for NHS use
Opportunistic bone-fragility screening
TBS Reveal™
Turn existing imaging into opportunity. AI software that surfaces bone-fragility risk opportunistically from routine X-rays.
- CE-marked, Class IIa
- Validation published in eClinicalMedicine (The Lancet Discovery Science)
Request a meeting
Can't find a time?
Tell us a little about you and we'll find a time at RSNA.
TBS Osteo™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Osteo is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). TBS Osteo is FDA 510(k) cleared (K243218) for use in the United States. TBS Osteo is included on the Australian Register of Therapeutic Goods (ARTG No. 528950) as "Inovanz Pty Ltd — X-ray system, diagnostic, general-purpose, application program software". Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
RBfracture™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. RBfracture is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 0123). RBfracture is included on the Australian Register of Therapeutic Goods (ARTG No. 484605) as “Emergo Asia Pacific Pty Ltd T/a Emergo Australia - X-ray image interpretive software”. Manufacturer: Radiobotics ApS, Esplanaden 8C, 1tv, 1263, Copenhagen, Denmark. Always follow the instructions for use.
TBS Reveal™ is intended exclusively for healthcare professionals and is not available for purchase by the general public. TBS Reveal is a Class IIa medical device, CE marked under EU MDR 2017/745 (CE 2460). FDA clearance is pending; TBS Reveal is not available for clinical use in the United States. Manufacturer: Medimaps Group SA, Chemin du Champ-des-Filles 36A, 1228 Plan-les-Ouates, Geneva, Switzerland. Always follow the instructions for use.
References (2)
1. Hans, D., Goertzen, A.L., Krieg, M.-A. and Leslie, W. D (2011). Bone Microarchitecture Assessed by TBS Predicts Osteoporotic Fractures Independent of Bone Density: The Manitoba Study. Journal of Bone and Mineral Research, 26(11), pp.2762–2769. doi:10.1002/jbmr.499.
2. Medimaps Group (2026) Internal data (data on file).